Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 海创药业股份有限公司(688302.SH)是一家专注于癌症和代谢性疾病的全球化创新药物企业,以“创良药·济天下”为使命,以为患者提供有效、安全、可负担的药物为重点,致力于研发和生产满足重大临床需求、具有全球权益的创新药物。公司拥有“PROTAC靶向蛋白降解技术平台、氘代药物研发平台、靶向药物发现与验证平台及转化医学技术平台”4大核心技术平台,承担2项国家“重大新药创制”科技重大专项和多个省市级科研项目,拥有13项在研产品。公司管理团队具有丰富药物研究、开发经验,核心成员多来自世界500强知名药企。公司现有产品管线中,AR拮抗剂氘恩扎鲁胺(HC-1119)正在中国和全球开展两项用于治疗去势抵抗性前列腺癌的III期临床试验,其中国III期临床试验已达到主要研究终点,临床III期数据入选2023年6月美国临床肿瘤学会(ASCO)年会,氘恩扎鲁胺HC-1119-04注册研究纳入2023版CSCO前列腺癌诊疗指南;URAT1抑制剂HP501单药用于治疗高尿酸血症/痛风已完成多项临床I/II期试验,正在开展III期临床试验相关准备工作;对消化道肿瘤具有潜在的治疗作用的HP558已在欧洲完成临床I期试验,II期临床试验申请已经获NMPA批准;HP518是中国首款进入临床阶段的口服ARPROTAC在研药物,正在澳大利亚开展用于治疗转移性去势抵抗性前列腺癌(mCRPC)的I期临床试验,此外,同适应症临床试验申请已获美国FDA批准;HP518中国临床试验申请于2023年11月获NMPA批准。
Main Business 癌症、代谢性疾病等具有重大市场潜力的治疗领域的创新药物研发
Legal Representative 陈元伟
Top Executives
董事长：陈元伟
董事：代丽,李兴海,陈元伦
独立董事：郑亚光,魏于全,彭永臣
Top 5 Shareholder
Shareholder name Nature Holding Date
AFFINITIS GROUP LLC限售股13.26%30/09/2024
成都盈创动力创业投资有限公司流通A股9.08%30/09/2024
陈元伦限售股3.87%30/09/2024
中国农业银行股份有限公司－鹏华医药科技股票型证券投资基金流通A股3.80%30/09/2024
Hinova United LLC限售股3.66%30/09/2024
Company Secretary 代丽
Solicitors 北京市君合律师事务所
Auditors 德勤华永会计师事务所（特殊普通合伙）
Tel No 028-85058465-8012
Fax No 028-85058465-8888
Website www.hinovapharma.com
Email ir@hinovapharma.com
Company Address
Register: 四川省成都市高新区科园南路5号蓉药大厦1栋4层附2、3号
Office: 四川省成都市高新区科园南路5号蓉药大厦1栋4层附2、3号
Listing Date 12/04/2022
Shares Capital
Shares Capital: 99,015,598
Total A Share: 99,015,598
Listed A Share: 72,724,459
Non-tradable A Share: 26,291,139
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -2.970
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 13.807
Market Capitalization(RMB) 2.395B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.